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The short arm of chromosome 8 is one of the most frequently
altered in breast cancer. Chromosome 8p abnormalities have
been associated with the development and/or progression of
breast cancer and 8p22 deletions have been associated with
more aggressive phenotypes and poorer survival (Yokota et al,
1999; Utada et al, 2000). Ampliﬁcation of the region 8p12, that
contains the neuregulin (NRG-1, also denominated heregulin)
gene, is detected in about 12% of breast tumours (Ade ￿laı ¨de
et al, 1994, 1998; Lee and Wood, 1993) and breakpoints in
bands 8p11-p21 have been reported in breast cancer (Morris
et al, 1997; Courtay-Cahen et al, 2000). The NRG-1 gene
encodes, by alternative splicing or by initiation of gene tran-
scripts at different sites, a family of more than 15 membrane
bound or secreted proteins most of which contain an extracel-
lular epidermal growth factor (EGF)-like domain (Peles and
Yarden, 1993). These proteins act as ligands for the HER family
of receptor tyrosine kinases and play an important role in cell
growth and differentiation, morphogenesis and apoptosis
(Burden and Yarden, 1997). Although NRG-1 was isolated
during the search for a HER-2 ligand (Holmes et al, 1992),
isoforms of NRG-1 bind to cells that express HER-3 or HER-
4 receptors alone, heterodimers of HER-2 with either HER-3
or HER-4 but not to cells that express monomers of HER-2
(Burden and Yarden, 1997).
Much interest in the neuregulins is based on the fact that
the receptors for these ligands, the HER family of proteins,
are ampliﬁed or over-expressed in breast cancer. HER-2 (also
known as neu and erbB2) gene ampliﬁcation and/or over-
expression are found in approximately one-third of breast
tumours and have been associated with a poor prognosis (Lupu
et al, 1996). NRG-1 induces an aggressive/invasive transformed
morphology in cultured mammary epithelial cells that express
HER-2 (Lupu et al, 1996) and can stimulate the growth of
breast cancer cells that express low levels of the HER-2 receptor
(Schaefer et al, 1997). Moreover, NRG-1 synthesised by the
mesenchyme has been implicated in mammary development
(Carraway et al, 1997), and it has been demonstrated that
NRG-1 induces proliferation or differentiation of various
mammary tumour cell lines, initiates programmed cell death
and induces cell differentiation in breast tumours (Ram et al,
1995; Weinstein et al, 1998; Le et al, 2000). Recently, it has
been identiﬁed in MDA-MB-175, a breast carcinoma cell line
that shows elevated levels of HER-2 (Lewis et al, 1993), a trans-
location between chromosomes 8p12-21 and 11q13 that leads to
the fusion of NRG-1 and DOC4 genes (Schaefer et al, 1997; Liu
et al, 1999; Wang et al, 1999; Ade ￿laı ¨de et al, 2000). This trans-
location generates a new chimeric transcript that codes for a
new isoform of the neuregulin family, denominated g-heregulin
(g-HRG), that acts as an autocrine growth factor in the breast
cancer cell line MDA-MB-175 (Schaefer et al, 1997).
In an attempt to deﬁne the incidence of this translocation in
Spanish women with breast cancer we have studied this
abnormality in a series of 141 breast carcinoma samples
collected at the University Hospital of Salamanca. All tumour
specimens were frozen immediately after removal and stored
at 7808C before processing. DNA was extracted as described
(Sa ￿nchez et al, 1995). The status of g-HRG gene was assessed
by Southern blot analysis. Genomic DNA was digested with
the restriction endonuclease EcoRI and electrophoresed on
0.8% agarose gels. DNA was blotted and hybridised with a
538 bp SacII-XhoI fragment (nt 209–747 from sequence
M94165) that spans the putative breakpoint site in chromosome
8p12.
Southern blot analysis of 141 primary breast carcinomas and
the MCF-7 breast cancer cell line did not reveal any abnormal
fragment. Our results show that the t(8;11)(p12;q13) transloca-
tion is not present in a large series of Spanish women with
breast cancer and conﬁrm previous reports that suggest that this
translocation is a particularity of the MDA-MB-175 cell line and
not a recurrent event (Wang et al, 1999; Ade ￿laı ¨de et al, 2000)
indicating that g-heregulin is not relevant in the development of
breast cancer.
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Early life exposure to oestrogen and testicular cancer risk:
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Testicular cancer has a peak incidence among men aged 25 to 34
years, suggesting early life inﬂuences (Akre et al, 1996). The
hypothesis that exposure to endogenous or environmental oestro-
genic compounds affects embryonic testis and increases the risk
of testicular cancer has been put forth (Sharpe and Skakkeback,
1993). This intriguing hypothesis has acquired momentum and,
in fact, was invoked as the main aetiologic mechanism in a recent
major review (Dearnaley et al, 2001). If prenatal exposure to
oestrogens were indeed important, one would expect that popula-
tions with higher levels of pregnancy oestrogens would experience a
higher rate of testicular cancer. We have studied pregnancy
hormone levels, including oestrogen levels, in two populations with
very different rates of testicular cancer (Lipworth et al, 1999).
Adult pregnant women were recruited from maternity clinics of
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